In vitro studies using immortalised cancer cell lines showed that butyrate has an overall positive effect on epithelial barrier integrity, but the physiological relevance of cancer cell lines is limited. We developed epithelial monolayers from human tissue samples of patients with ulcerative colitis [UC] to assess the effect of butyrate on epithelial barrier function. Methods: A protocol to establish monolayers from primary epithelial cells of UC patients [n = 10] and non-UC controls [n = 10] was optimised. The monolayers were treated with 8 mM sodium butyrate ± tumour necrosis factor alpha [TNFα] and type II interferon [IFNγ] for 48 h. Changes in transepithelial electrical resistance were monitored. Barrier gene expression levels were measured. Inflammatory proteins in the supernatant of the cells were quantified with OLINK. Results: We demonstrated that primary monolayer cultures can be grown within 1 week of culture with robust resistance values and polarised tight junction expression. Butyrate treatment of the cultures increased resistance but was detrimental in combination with TNFα and IFNγ. The combined treatment further induced even higher IL8 mRNA and inflammatory protein secretion than for the inflammatory mediators alone. The observed effects were similar in cultures from patients and non-UC controls, suggesting that there were no patient-specific responses responsible for these findings.
Introduction
Ever since the first observations of increased intestinal permeability in patients with inflammatory bowel disease [IBD] , dysfunction of the intestinal barrier has been recognised to play a major role in the multifactorial pathogenesis of IBD. 1, 2 Besides the mucus layer, the intestinal epithelial cells represent a key feature of the intestinal barrier where they provide a physical and immunological defence mechanism to protect the host against invading pathogenic microorganisms and potentially harmful molecules. Regulation of the intestinal barrier is highly complex and involves several internal and exogenous factors including the gut microbiota and its metabolites. 3, 4 In IBD patients, alterations in the gut microbiota, also termed dysbiosis, have been defined as decreased microbial diversity compared with healthy individuals and changes in abundance of specific bacterial taxa. 5 Among these, for example, a decrease of short-chain fatty acid-producing bacteria belonging to the phylum Firmicutes has been consistently found in stools of IBD patients. [5] [6] [7] Short-chain fatty acids are the primary end products of fermentation of nondigestible carbohydrates in the large intestine, and provide a direct mechanistic link between intestinal dysbiosis, barrier dysfunction, and IBD pathogenesis. 8 Whereas acetate has the highest concentrations in the gut, butyrate is the most well-known short-chain fatty acid for its pleiotropic effects.
Butyrate is the major energy source for colonocytes, and was shown to be involved in anti-inflammatory processes, oxidative stress pathways, regulation of cell proliferation and differentiation, colonic defence, satiety, immune regulation, and intestinal barrier function. 9 Given these reported positive effects and the proven lack of butyrate-producing bacteria in IBD patients, supplementation of butyrate has been repeatedly proposed in the management of IBD colitis. However, the clinical effects of butyrate treatment, in particular using enemas, have been inconsistent across studies ranging from beneficial effects on inflammatory parameters to very mild or no improvement. [10] [11] [12] [13] [14] [15] Data from murine colitis models have also been contradictory and even showed influence on tumour formation in mice, stressing the need for additional studies on the basic mechanisms of butyrate and other short-chain fatty acids. [16] [17] [18] [19] [20] [21] With regard to the effect of butyrate on intestinal barrier function, most researchers are using intestinal cell lines including Caco-2 and HT-29 monolayers as model systems. In these models, butyrate enhances epithelial barrier function and tight junction protein expression, although the observed changes are often dependent on the concentration of butyrate and the type of cells. 9, 22 Caco-2 cells have the advantage that they are easy to culture and differentiate spontaneously to enterocytes, but they are derived from a human colon carcinoma and thus do not fully resemble the expression patterns and behaviour of normal intestinal epithelial cells. 23 Recently, there is a growing interest in the use of primary intestinal epithelial cells as an alternative in vitro model for studies of human intestinal epithelia. 24 Although these models have been challenging due to limitations in cell viability and cell number, recent advances with organoid cultures derived from human biopsies have overcome these hurdles. 25 Using the proliferative power of epithelial spheroids to expand primary epithelial cells of patients on Transwell filters, the group of VanDussen et al. previously showed that adherence of specific pathogens to primary cells was enhanced compared with immortalised cells, again confirming the importance of the origin of the cells. 26 Considering the lack of results in human primary tissue for butyrate and the inconsistent clinical data in IBD, we studied the effects of butyrate treatment on primary intestinal epithelial monolayers of patients, to untangle the mechanisms of the metabolite on epithelial barrier function. We first optimised a protocol to obtain epithelial cell cultures from endoscopically derived biopsies of patients with ulcerative colitis [UC] in Transwell inserts. Using this model, we then analysed the effect of butyrate in combination with the inflammatory mediators tumour necrosis factor alpha [TNFα] and interferon type II [IFNγ] on barrier function including changes in: epithelial resistance; gene expression levels of selected genes related to the intestinal barrier; and inflammatory protein secretion in the supernatant of the cell monolayers.
Materials and Methods

Human biopsy collection and ethical statement
Mucosal biopsies from macroscopically non-inflamed colon were obtained during routine endoscopy from 10 UC patients and 10 non-UC controls at the University Hospitals Leuven. Previous inflammation at the site of biopsy extraction for UC patients was not excluded, nor active inflammation at other parts of the large intestine. Non-UC controls were individuals undergoing colonoscopy for surveillance of colorectal polyps or abdominal discomfort, but without abnormalities found. The biopsies were collected in ice-cold basal medium [ 
Intestinal crypt isolation and organoid culture
Intestinal crypts were isolated from 4-6 colon biopsies per individual as described before. 27 At the end of the procedure, the crypts were re-suspended in Matrigel [Growth Factor Reduced, phenol-red-free, Corning, NY, USA] diluted with basal medium [50/50%]. 28 To allow the formation of 3D organoid structures, three droplets [13.3 μl] of each cell suspension were plated in every well of a 24-well tissue culture plate [8-12 wells/4-6 biopsies dependent on biopsy size and isolation efficiency]. After polymerisation of the Matrigel mixture in a humidified incubator at 37°C and 5% CO 2 for at least 30 min, 500 μl human expansion medium [HM] [see Supplementary Table 1 , available as Supplementary data at ECCO-JCC online for a list with the components] was added to the wells to let the organoids grow over time. The medium was replaced every 48 h, and the organoids were split after 7-10 days [usually 1:3 split] depending on their growth rate. Of every new culture, at least four wells with a low passage number [P2-P10] were pelleted, re-suspended in 1 ml Recovery Cell Culture Freezing Medium [Gibco] and stored in liquid nitrogen to obtain an organoid stock. Different sample aliquots were stored from each culture, allowing for future or additional experiments within the same individual. For each monolayer experiment, one sample aliquot with colonic organoids was slowly thawed, re-suspended in Matrigel mixture, and expanded until sufficient wells were obtained.
Primary epithelial cell monolayer culture
The protocol to form primary epithelial cell monolayers on membrane inserts from organoids was based on the protocol from VanDussen et al. with slight modifications. 26 , approximately three wells with organoids of a 24-well plate per Transwell were harvested and dissociated mechanically by pipetting up and down 10 times using a 200-μl tip on top of a 1000-μl tip and pipette. All organoids were harvested between passage numbers 2 and 10. The organoid fractions were subsequently washed in 0.5-mM EDTA/PBS solution and centrifuged for 5 min at 350 g. The fractions were then treated with 0.25% trypsin/EDTA [Gibco] for 5 min at 37°C in a water bath. The fractions were further dissociated mechanically with a pipette until a homogeneous solution without visible aggregates was obtained. We also checked the fractions regularly under a standard light microscope to evaluate the size of the aggregates. With cell aggregates of 2-10 cells, trypsin was inactivated using an excess of BM supplemented with 10% fetal bovine serum. The cells were spun down in the solution at 350 g for 5 min. The pellet was again re-suspended in BM and the number of aggregates was manually counted. After counting, the cells were centrifuged and finally dissolved in the correct volume of 50% HM + ROCK inhibitor to seed approximately 1 x 10 6 cells in 100 μl in each Transwell insert [apical compartment]. The lower compartment of the wells was filled with 600 μl of 50% HM + ROCK inhibitor. To let the aggregates attach and grow, the cells were kept at 37°C in a humidified incubator with 5% CO 2 . After 24 h, dead and unattached cells were washed away by carefully pipetting up and down without touching the membrane. The medium in the apical [200 μl] and basolateral compartments [600 μl] was refreshed with 50% HM without ROCK inhibitor, and this was repeated every other day until confluent and polarised monolayers were formed. Imaging of the living cell monolayers was performed with a Zeiss Axiovert 40 CFL 
Haematoxylin and eosin staining and immunofluorescence
Stainings were performed either on transverse sections or on whole mounts of the monolayers. Primary antibodies for immunofluorescence included mouse anti-ZO1 antibody [ [29] [30] [31] [32] [33] [34] and a pilot study in our laboratory with 50 ng/ml of the components [ Supplementary Figures 1 and 2 , available as Supplementary data at ECCO-JCC online]. Cells grown in 50% HM were used as negative control condition. All conditions were tested in duplicate and the treatments were initiated when the cell monolayers showed polarisation based on resistance and visual evaluation [usually 5-7 days after seeding in the Transwells]. Sodium butyrate was added to the medium of the upper [apical or luminal side] compartment of the Transwells, and TNFα and IFNγ were administered to the medium of the basolateral compartment of the 24-well culture plates. Cells were treated for 48 h, after which they were used for RNA extraction. The apical and basolateral media were harvested and stored at -80°C for protein measurements.
Transepithelial electrical resistance measurements
Transepithelial electrical resistance [TEER] measurements were performed using an EVOM2 epithelial Volt/Ohm meter and STX2 chopstick electrode set [World Precision Instruments, Sarasota, FL, USA]. All measurements were performed in triplicate and corrected with the resistance value of an empty Transwell insert. Final values were calculated as the average resistance multiplied by the area [0.33 cm 2 ] of the Transwell membrane and expressed as Ω.cm 2 .
Gene expression analysis by quantitative reverse transcription
Cells were immersed in RNA lysis buffer [Qiagen, Hilden, Germany] with 2-mercaptoethanol [Sigma-Aldrich], and lysates were kept at -80°C until RNA extraction. Total RNA isolation was performed using the RNeasy Mini Kit [Qiagen]. Complementary DNA was synthesised from 0.22 μg total RNA using the RevertAid TM H Minus First strand cDNA Synthesis kit [Fermentas, Thermo Fisher Scientific] according to the manufacturer's protocol. The expression of some of the major genes involved in intestinal barrier function was studied: claudin 1 [CLDN1], claudin 2 [CLDN2], claudin 8 
Results
Establishment of tight monolayer cultures from primary intestinal epithelial cells in Transwells is feasible within 1 week
We first set out to obtain confluent monolayer cultures from primary intestinal epithelial cells of human colon organoids from UC patients and non-UC controls in Transwells. To evaluate the efficiency of our procedure, we measured TEER every 24 h after cell seeding, and performed haematoxylin and eosin [H&E] and immunostaining. First, we observed that the TEER values rapidly increased a few days after seeding in all cultures [ Figure 1A ]. Figure 1C ]. The apical-basolateral polarisation of the cells was confirmed using Z-stack images. At a depth of 2.5 µm, ZO1 and CLDN3 showed a clear fluorescent signal with co-localisation [as indicated by the overlap of the fluorescent signals], whereas this signal disappeared when moving towards the basolateral side where the DAPIstained nuclei became clearly visible at a depth of 6 µm [ Figure 1D ].
Butyrate is detrimental for intestinal barrier integrity and cell appearance in the presence of inflammatory mediators
When adding 8mM butyrate to the primary monolayer cultures, we found an overall beneficial effect on TEER of the cells, with a significant increase over a time period of 48 h compared with the negative control condition (two-way analysis of variance [ANOVA], adj.p <0.0001; Figure 2A ). Although medium complemented with TNFα and IFNγ alone had a very limited negative effect on TEER over time [two-way ANOVA, adj.p = 0.14; Figure  2A ], co-incubation of the monolayers with these inflammatory mediators and butyrate led to a large, significant drop in TEER [twoway ANOVA, adj.p <0.0001; Figure 2A ]. Figure 2B ). Brightfield microscopic images of the cultures at the end of the treatments were in agreement with the TEER findings and showed confluent monolayers for the untreated control condition and butyrate treatment condition, whereas the morphology of the cells was slightly altered in the presence of TNFα and IFNγ, and even more so in the combined treatment condition [ Supplementary Figure 6 , available as Supplementary data at ECCO-JCC online].
Butyrate treatment has divergent though disease-independent effects on epithelial barrier gene expression
Given the observed TEER and microscopic changes, we also evaluated the mRNA expression levels of a selection of intestinal barrier this did not remain significant when corrected for multiple testing [Mann-Whitney U test, unadj.p = 0.01; Supplementary Figure 8 , available as Supplementary data at ECCO-JCC online].
Butyrate induces high inflammatory protein expression upon induction with TNFα and IFNγ
To evaluate the expression of secreted proteins upon cell treatment, we measured a panel of 40 inflammation-related proteins in the upper and lower compartment media of the treated monolayers. Unsupervised clustering showed that the negative control condition and butyrate-treated samples largely overlapped and were distinct from the samples treated with the inflammatory mediators TNFα and IFNγ and its combination with butyrate (principal component analysis [PCA]; Figure 4 ). The PCA plot furthermore showed a second separation of the samples dependent on the medium com- Table 2 ]). All proteins were significantly upregulated for these comparisons. For the combination treatment of butyrate and TNFα and IFNγ, we identified a total of 18 and 13 significantly altered proteins in the apical and basolateral media, respectively, as compared with the negative control media samples of these cultures (>2-fold change, paired Wilcoxon adj.p <0.05; BUT + TNF-IFN vs CTRL [ Table 2 ]). The majority of proteins were common with those seen for the treatment condition with TNFα and IFNγ alone, although generally higher increases in protein concentrations were observed for the combination with butyrate versus the control condition. A Venn diagram showing the distribution of the differentially expressed proteins in the different treatment groups is given in Supplementary Figure 9 , available as Supplementary data at ECCO-JCC online.
Discussion
In this study, we could efficiently obtain confluent and polarised monolayer cultures in Transwell inserts from primary epithelial cells of UC patients and non-UC controls. Using this model to better mimic the physiological situation than earlier studies with immortalised cancer cell lines, we first confirmed that butyrate has a beneficial effect on barrier resistance, but we also observed a surprising, negative effect of butyrate on TEER and visual appearance of the epithelial cell monolayers in the presence of the inflammatory mediators TNFα and IFNγ. The combined treatment of butyrate with TNFα and IFNγ also induced a strong upregulation of IL8 mRNA expression and many inflammatory proteins. These treatment responses were, however, not dependent on disease-related signatures of the epithelial cells, because cultures from UC patients did not differ at any point from those of non-UC controls, similarly not at baseline. Together our results underscore the need of revisiting the basic mechanisms of butyrate with improved human model systems.
The use of primary intestinal epithelial monolayer cultures in permeable inserts has been of interest to a growing number of researchers. 24, 26, [36] [37] [38] The protocol enables investigation of mechanisms and responses in a patient-specific manner with easy access to the apical and basolateral side of epithelial cells, which is a great advantage as compared with the use of organoid cultures where the lumen is enclosed. Similar to the results of VanDussen et al. whose protocol and expertise were used as guidance, 26 we obtained polarised monolayers consisting of a mix of differentiated intestinal epithelial cells, including colonocytes and MUC2-producing cells, and proliferative Ki67-positive cells. H&E staining confirmed confluency of the monolayers across the Transwell inserts, which was fundamental for the set up of this study. As evidenced by the high TEER values, the monolayers also showed clear tight junction protein expression including CLDN3 and ZO1.
Butyrate has generally been seen as a positive regulator of intestinal barrier function. [39] [40] [41] [42] Peng et al., however, showed that the effect of butyrate can also be paradoxical dependent on the applied dose: whereas low concentrations [2 mM] of butyrate promoted barrier function in Caco-2 cells, high concentrations [8 mM] induced intestinal cell apoptosis and reduced TEER. 43 Here, epithelial monolayers were exposed to 8 mM butyrate which was considered a physiologically relevant concentration for primary epithelial colon cells based on literature, and indeed showed an evident, increased TEER without induction of apoptosis.
Researchers have shown that primary colon cells can tolerate higher concentrations of butyrate compared with cancer cells, due to differences in cell origin and behaviour, again confirming the importance of a primary human tissue model. 44 An intermediate dose of 4 mM also demonstrated higher TEER values in our cultures, although the percentage increase was much lower at the end of the treatment period [ Supplementary Figure 10 , available as Supplementary data at ECCO-JCC online]. Since intestinal barrier function should not be assessed with TEER measurements alone, which mostly reflect permeability to ions, 45 we also investigated changes in expression of tight junction proteins. The TEER-associated changes in mRNA expression of some well-known epithelial barrier genes showed increased values for all but one barrier gene in the butyrate-treated cultures as compared with the negative controls, with the strongest upregulations seen for CLDN1 and OCLN. CLDN2 was the only gene that was significantly downregulated.
As opposed to CLDN1 and OCLN, but also CLDN8, MUC2, and ZO1 that are encoding barrier-enhancing proteins, CLDN2 is a pore-forming tight junction protein and thus barrier-deteriorating. 46 These results are in line with previous studies, although for CLDN1, increased mRNA expression levels in IBD patients with active clinical disease have also been observed. 47, 48 This would imply that CLDN1 levels are associated with barrier dysfunction in active IBD, but this is in contrast with the observed increased TEER values in the cultures. A potential explanation could be that the function of CLDN1 is dual and dependent on the disease environment or other tight junction proteins. Although part of the barrier-forming tight junction complex in steady-state conditions, its role might be altered during the disease process. For the upstream regulator of the tight junctions, HIF1A, increased mRNA levels were found in the butyrate-treated cultures as compared with the untreated controls, again suggesting a protective effect of the metabolite for epithelial barrier function as previously also seen in Caco-2 cells and mice models. 49, 50 This positive effect is further confirmed by increased expression of the epithelial cell marker VIL1 and a known effect on epithelial cell differentiation as reflected by the lower MKI67 values. 51 At the same time, however, the mRNA expression of IL8 was significantly increased in butyrate-treated cultures as compared with untreated control cultures, independent of co-stimulation with the inflammatory mediators TNFα and IFNγ. Albeit this has been described before, the mechanism behind this effect remains to be elucidated. 41 Since inflammation is a central process of IBD, we included TNFα and IFNγ as pro-inflammatory mediators in our system. The TEER values with these mediators alone decreased by 14.1% as compared with the negative control cultures. This effect was modest, as also reflected by the unchanged IL8 mRNA expression values in these cultures at 48 h. We did, however, observe a visual effect on the appearance of the cell monolayers, suggesting that we nonetheless induced a pro-inflammatory environment which was also implied by the higher levels of the inflammatory proteins. Previous studies have shown that combined TNFα and IFNγ treatment indeed provokes an inflammatory milieu in a synergistic manner in monolayer cultures, and can be associated with increased paracellular permeability and displacement or downregulation of tight junction proteins. 52 Compared with most other studies that are using concentrations ranging from 50 ng/ ml to 100 ng/ml, the TNFα and IFNγ concentrations in our study were rather low since we wanted to limit profound epithelial damage in this condition due to cell viability decreases. 29, 53 When using double concentrations [50 ng/ml] of the cytokines, the gene expression alterations showed similar trends with higher relative changes, but also more extreme TEER decreases [ Supplementary Figures 1 and 2] . Because the epithelial cells were derived from non-inflamed areas in the UC patients, we did not expect to see high baseline inflammatory marker expression levels. Indeed, the non-treated cells showed low IL8 expression and had robust and high TEER values. Furthermore, the mRNA levels of IL8 were not different when compared with those from non-UC controls. To create an inflammatory milieu in the cell monolayers, addition of the stimuli was thus needed in both cultures from UC patients and non-UC controls. Additionally, data from our group have previously shown that the inflammatory status of mucosal biopsies is not propagated to organoid cultures, and an external stimulus is needed for continued expression of this status. 54 Conversely, it is possible that UC patients have imprinted alterations in other genes of the colonic epithelium, driving pathology and altering their responses to stimuli. 55 Yet, we did not find evidence for this for the epithelial barrier genes that we selected.
Our most surprising results were observed for the combination treatment of butyrate with the pro-inflammatory cytokines TNFα and IFNγ, the condition which we believe is most relevant in the context of IBD. In a Caco-2 cell model, Eeckhaut et al. demonstrated that supernatant of Butyricicoccus pullicaecorum-a major butyrate producer-prevented the loss of TEER and increase in IL8 secretion induced by TNFα and IFNγ. 56 We however found here that butyrate worsens TEER and cell appearance in the presence of these inflammatory mediators, and IL8 mRNA gene expression was highly upregulated as compared with the negative control media samples. The effects on barrier gene mRNA levels were less pronounced, with most having levels comparable to the control medium condition. The discrepancies between the detrimental effects in our study with previously published data are probably associated with the fact that earlier studies always used cancer cell lines as in vitro models, which do not reflect the normal physiology of primary human colon epithelial cells as previously discussed, and thus do not give us the whole picture of the epithelial functions of butyrate, in particular during inflammation. 57 This is further evidenced by a study of Chang et al. who showed that butyrate could not ameliorate colitis in diaminodiphenyl-sulphone [DDS]-treated mice. 17 A potential mechanism behind these observations and the data we present was recently also described by the group of Kaiko et al., who identified that colonic crypts protect stem cells in vivo from high butyrate concentrations. 58 The overlying layer with differentiated colonocytes would serve as a metabolic barrier and prevent the metabolite reaching the progenitor cells in the crypts where it inhibits stem cell proliferation. They suggest that exposure of proliferating cells to butyrate in cases of mucosal injury can delay wound repair-a mechanism which could also be responsible for the detrimental effects seen in the cultures from this study which are concomitantly exposed to the inflammatory mediators TNFα and IFNγ.
Quantification of a panel of inflammation-related proteins in the apical and basolateral media samples of the cell cultures confirmed that butyrate does not counteract the induction of a proinflammatory milieu by TNFα and IFNγ, but induced even higher levels of many inflammatory proteins as compared with the condition with TNFα and IFNγ alone. There was also a significant upregulation of the apoptosis-related protein CASP8 for the combination treatment condition which might explain some of the effects seen on cell morphology. Finally, given that more than 200 genetic loci have been associated with IBD, and part of these loci have been attributed to epithelial barrier genes and intestinal integrity pathways, UC patients could have an increased genetic predisposition to functional barrier defects. 59, 60 In a previous study from our group, we observed measurable defects in epithelial ER stress handling in patients with many IBD-associated endoplasmic reticulum [ER] stress variants versus those carrying less variants. 27 Likewise, we here evaluated whether UC patients had different TEER and barrier gene levels compared with non-UC controls who are expected to carry substantially less disease-associated alleles. Although we found large inter-individual differences in TEER and barrier gene levels, there was no general difference for the median levels between UC patients and non-UC controls. Neither baseline differences nor altered response rates to the different treatment conditions were observed, indicating that patients do not need higher/other butyrate concentrations or are more sensitive than healthy controls. We however did not specifically evaluate the genetic variants in the included patients, which would allow stratification of the patients in genetic risk groups and could possibly show a better distinction.
In conclusion, we developed a valuable ex vivo approach to assess the effect of different molecules/therapies on barrier function of primary epithelial cells from IBD patients. Using this model, we demonstrated that butyrate supplementation could not counteract the negative effects of TNFα and IFNγ on epithelial barrier function, but even worsened the negative effects on TEER, and strongly upregulated inflammatory mRNA and protein expression. We suggest that the addition of the inflammatory mediators induced barrier dysfunction and mucosal damage mechanisms in the cultures, which make the cells oversensitive to butyrate with subsequent inhibition of cell proliferation and repair, as recently shown in intestinal crypts. Together our observations confirm that additional studies are needed to provide a more nuanced understanding of the effects of butyrate on epithelial barrier function.
